{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:28:49Z","timestamp":1790710129063,"version":"4.1.0"},"reference-count":68,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>There is currently no consensus on whether the combination therapy of Vitamin D (VitD) and bisphosphonates offers superior efficacy compared to monotherapy in the treatment of postmenopausal osteoporosis. The aim of this study is to conduct a meta-analysis of recent relevant research to synthesize the available evidence and further investigate whether the combined use of VitD and bisphosphonates is superior to monotherapy in treating osteoporosis in postmenopausal women.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and results<\/jats:title><jats:p>We systematically searched PubMed, EMBASE, the Cochrane Library, and Web of Science for randomized controlled trials (RCTs) comparing the effects of monotherapy with VitD or bisphosphonates <jats:italic>versus<\/jats:italic> their combination therapy in the treatment of postmenopausal osteoporosis, up to 1 February 2024. The articles were independently screened and relevant data were extracted by two investigators. The changes in mean values and percentage changes for bone resorption markers, bone formation markers, bone mineral density, and bone mineral metabolism markers were expressed using the standardized mean difference (SMD) and 95% confidence intervals (CI). Heterogeneity was quantitatively described using the I<jats:sup>2<\/jats:sup> test. Subsequently, sensitivity analyses were performed for data with significant heterogeneity. Subgroup analyses were conducted based on the type of monotherapy used, and potential publication bias was assessed. The analysis revealed that the combination of VitD and bisphosphonates demonstrated a more pronounced effect in increasing alkaline phosphatase (ALP), 25-hydroxyvitamin D (25-OH-VD), and serum calcium (sCa) levels, as well as in decreasing levels of serum bone-specific alkaline phosphatase (sBALP), serum C-terminal telopeptide of type I collagen (sCTX), and urinary N-telopeptide of type I collagen (UriNTX) compared to the monotherapy group. However, the combination of VitD and bisphosphonates did not show a significant advantage over monotherapy in terms of improving osteocalcin levels. The differences in the mean changes in osteocalcin, UriNTX, and sCa, as well as the percentage changes in parathyroid hormone (PTH) were not statistically significant (<jats:italic>p<\/jats:italic> &amp;gt; 0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The meta-analysis suggests that compared to monotherapy, the combination therapy of VitD and bisphosphonates exhibits a more favorable effect on bone mineral density and bone calcium metabolism-related markers in the treatment of postmenopausal osteoporosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p><jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/PROSPERO<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1422062","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T04:43:22Z","timestamp":1732164202000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy of combination therapy of vitamin D and bisphosphonates in the treatment of postmenopausal osteoporosis: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Yuangui","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanyi","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feibin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00223-008-9179-5","article-title":"Intramuscular neridronate in postmenopausal women with low bone mineral density","volume":"83","author":"Adami","year":"2008","journal-title":"Calcif. Tissue Int."},{"key":"B2","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1111\/j.1532-5415.2007.01161.x","article-title":"Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial","volume":"55","author":"Barone","year":"2007","journal-title":"J. Am. Geriatr. Soc."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1210\/jc.2019-00192","article-title":"Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis","volume":"104","author":"Barrionuevo","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1002\/jbmr.2847","article-title":"Potential usefulness of BMD and bone turnover monitoring of zoledronic acid therapy among women with osteoporosis: secondary analysis of randomized controlled trial data","volume":"31","author":"Bell","year":"2016","journal-title":"J. Bone Min. Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1210\/jcem.87.6.8575","article-title":"Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women","volume":"87","author":"Bell","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/s0149-2918(00)87974-6","article-title":"Weekly administration of alendronate: rationale and plan for clinical assessment","volume":"22","author":"Bone","year":"2000","journal-title":"Clin. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/s8756-3282(03)00084-x","article-title":"Intravenous intermittent neridronate in the treatment of postmenopausal osteoporosis","volume":"33","author":"Braga","year":"2003","journal-title":"Bone"},{"key":"B8","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/BF03345373","article-title":"Effects of neridronate treatment in elderly women with osteoporosis","volume":"28","author":"Cascella","year":"2005","journal-title":"J. Endocrinol. Investig."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1007\/s00198-014-3000-2","article-title":"Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism","volume":"26","author":"Cesareo","year":"2015","journal-title":"Osteoporos. Int."},{"key":"B10","first-page":"306","article-title":"The efficacy of alendronate in the prevention and treatment of postmenopausal osteoporosis","volume":"24","author":"Cheng","year":"2002","journal-title":"efficacy alendronate Prev. Treat. postmenopausal Osteoporos."},{"key":"B11","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1136\/bmj.309.6956.711","article-title":"Fortnightly Review: the therapeutic use of bisphosphonates","volume":"309","author":"Compston","year":"1994","journal-title":"Bmj Clin. Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1056\/NEJM199808063390601","article-title":"Reduction in new metastases in breast cancer with adjuvant clodronate treatment","volume":"339","author":"Diel","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s00198-005-0035-4","article-title":"Changes in the RANK ligand\/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients","volume":"17","author":"Dobnig","year":"2006","journal-title":"Osteoporos. Int."},{"key":"B14","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s00774-009-0055-9","article-title":"The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study","volume":"27","author":"Dundar","year":"2009","journal-title":"J. Bone Min. Metab."},{"key":"B15","first-page":"34","article-title":"Additive impact of alfacalcidol on bone mineral density and bone strength in alendronate treated postmenopausal women with reduced bone mass","volume":"11","author":"Felsenberg","year":"2011","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1210\/jc.2009-1703","article-title":"Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis","volume":"95","author":"Finkelstein","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B17","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2165\/00044011-199815030-00008","article-title":"Effects of combined treatment with calcitriol plus alendronate on bone mass and bone turnover in postmenopausal OsteoporosisTwo years of continuous treatment","volume":"15","author":"Frediani","year":"1998","journal-title":"Clin. drug Investig."},{"key":"B18","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.bone.2008.03.008","article-title":"Stimulation of osteogenic differentiation and inhibition of adipogenic differentiation in bone marrow stromal cells by alendronate via ERK and JNK activation","volume":"43","author":"F","year":"2008","journal-title":"Bone"},{"key":"B19","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1001\/jamainternmed.2015.0747","article-title":"Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial","volume":"175","author":"Greenspan","year":"2015","journal-title":"JAMA Intern Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1365-2249.2005.02665.x","article-title":"The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins","volume":"139","author":"Hewitt","year":"2005","journal-title":"Clin. Exp. Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"4743","DOI":"10.1210\/endo.139.11.6433","article-title":"Orthotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells","volume":"139","author":"Horwood","year":"1998","journal-title":"Endocrinology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/j.jfma.2023.01.013","article-title":"Asia-pacific consensus on osteoporotic fracture prevention in postmenopausal women with low bone mass or osteoporosis but no fragility fractures","volume":"122","author":"Huang","year":"2023","journal-title":"J. Formos. Med. Assoc."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/ggi.12340","article-title":"Status of prevalence study on multimorbidity of chronic disease in China: systematic review","volume":"15","author":"Hu","year":"2015","journal-title":"Geriatr. Gerontol. Int."},{"key":"B24","article-title":"GRADE your evidence and improve your guideline development in health care","author":"Inc","year":"2021","journal-title":"GRADEpro GDT"},{"key":"B25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/TCRM.S54772","article-title":"Eldecalcitol improves chair-rising time in postmenopausal osteoporotic women treated with bisphosphonates","volume":"10","author":"Iwamoto","year":"2014","journal-title":"Ther. Clin. Risk Manag."},{"key":"B26","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1007\/s00776-003-0655-5","article-title":"Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis","volume":"8","author":"Iwamoto","year":"2003","journal-title":"J. Orthop. Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.3109\/09513590.2011.579657","article-title":"The effect of risedronate treatment on serum osteoprotegerin and bone marker levels in postmenopausal women with osteoporosis","volume":"27","author":"Karadag-Saygi","year":"2011","journal-title":"Gynecol. Endocrinol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1345\/aph.1P439","article-title":"Vitamin D status and response to daily 400 IU vitamin D3 and weekly alendronate 70 mg in men and women with osteoporosis","volume":"45","author":"Karaplis","year":"2011","journal-title":"Ann. Pharmacother."},{"key":"B30","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3349\/ymj.2014.55.3.715","article-title":"Efficacy and safety of weekly alendronate plus vitamin D\u2083 5600 IU versus weekly alendronate alone in Korean osteoporotic women: 16-week randomized trial","volume":"55","author":"Kim","year":"2014","journal-title":"Yonsei Med. J."},{"key":"B31","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.bone.2004.10.014","article-title":"The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: a randomized placebo-controlled study","volume":"36","author":"Leung","year":"2005","journal-title":"Bone"},{"key":"B32","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1210\/edrv.22.4.0437","article-title":"Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications","volume":"22","author":"Lips","year":"2001","journal-title":"Endocr. Rev."},{"key":"B33","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.beem.2011.05.002","article-title":"The effect of vitamin D on bone and osteoporosis","volume":"25","author":"Lips","year":"2011","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"key":"B34","doi-asserted-by":"publisher","first-page":"5713","DOI":"10.1158\/1078-0432.CCR-15-3086","article-title":"Changes in bone turnover marker levels and clinical outcomes in patients with advanced cancer and bone metastases treated with bone antiresorptive agents","volume":"22","author":"Lipton","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/BF02242451","article-title":"The effect of a modified etidronate cyclical regimen on postmenopausal osteoporosis: a four-year study","volume":"16","author":"Lyritis","year":"1997","journal-title":"Clin. Rheumatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1136\/ard.57.6.346","article-title":"Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women","volume":"57","author":"Masud","year":"1998","journal-title":"Ann. Rheum. Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s00198-008-0816-7","article-title":"Effect of daily oral mindoroate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study","volume":"20","author":"Matsumoto","year":"2009","journal-title":"Osteoporos. Int."},{"key":"B38","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.bone.2008.09.011","article-title":"Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss","volume":"44","author":"Mcclung","year":"2009","journal-title":"Bone"},{"key":"B39","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.amjmed.2012.06.023","article-title":"Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday","volume":"126","author":"Mcclung","year":"2013","journal-title":"Am. J. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2741\/409","article-title":"Vitamin-D regulation of bone mineralization and remodelling during growth","volume":"4","author":"Morris","year":"2012","journal-title":"Front. Biosci. Elite Ed."},{"key":"B41","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s00223-014-9840-0","article-title":"Vitamin D status and parathyroid hormone concentrations influence the skeletal response to zoledronate and denosumab","volume":"94","author":"Mosali","year":"2014","journal-title":"Calcif. Tissue Int."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1359\/JBMR.050403","article-title":"Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover","volume":"20","author":"Nenonen","year":"2005","journal-title":"J. Bone Min. Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s12282-016-0695-2","article-title":"Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases","volume":"24","author":"Nishimukai","year":"2017","journal-title":"Breast Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1210\/jc.2012-2999","article-title":"Effects of 25-hydroxyvitamin D3 therapy on bone turnover markers and PTH levels in postmenopausal osteoporotic women treated with alendronate","volume":"97","author":"Olmos","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B44","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"B45","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3760\/cma.j.cn112141-20220220-00108","article-title":"A randomized double-blinded placebo-controlled clinical trial of mindoroate tablet in postmenopausal Chinese women with osteoporosis","volume":"57","author":"Peng","year":"2022","journal-title":"Zhonghua Fu Chan Ke Za Zhi"},{"key":"B46","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ajog.2007.07.022","article-title":"Combination therapy for treatment of osteoporosis: a review","volume":"197","author":"Pinkerton","year":"2007","journal-title":"Am. J. Obstet. Gynecol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/jbmr.1775","article-title":"Effects of zoledronate versus placebo on spine bone mineral density and microarchitecture assessed by the trabecular bone score in postmenopausal women with osteoporosis: a three-year study","volume":"28","author":"Popp","year":"2013","journal-title":"J. Bone Min. Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/S0140-6736(10)62349-5","article-title":"Osteoporosis: now and the future","volume":"377","author":"Rachner","year":"2011","journal-title":"Lancet"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1185\/030079906x120913","article-title":"Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial","volume":"22","author":"Recker","year":"2006","journal-title":"Curr. Med. Res. Opin."},{"key":"B50","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.bone.2004.01.008","article-title":"Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis","volume":"34","author":"Recker","year":"2004","journal-title":"Bone"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1007\/s00198-006-0200-4","article-title":"Effects of a combined alendronate and calcitriol agent (Maxmarvil) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study","volume":"17","author":"Rhee","year":"2006","journal-title":"Osteoporos. Int."},{"key":"B52","doi-asserted-by":"publisher","first-page":"6222s","DOI":"10.1158\/1078-0432.CCR-06-0843","article-title":"Molecular mechanisms of action of bisphosphonates: current status","volume":"12","author":"Roelofs","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"115493","DOI":"10.1016\/j.bone.2020.115493","article-title":"Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton","volume":"139","author":"Rogers","year":"2020","journal-title":"Bone"},{"key":"B54","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/s8756-3282(00)00291-x","article-title":"Effects of two intermittent alendronate regimens in the prevention or treatment of postmenopausal osteoporosis","volume":"27","author":"Rossini","year":"2000","journal-title":"Bone"},{"key":"B55","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ecl.2021.03.010","article-title":"Update on approved osteoporosis therapies including combination and sequential use of agents","volume":"50","author":"Saul","year":"2021","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"B56","first-page":"1","article-title":"Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group","volume":"12","author":"Schnitzer","year":"2000","journal-title":"Aging (Milano)"},{"key":"B57","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s007760100060","article-title":"Effect of intermittent cyclical treatment with etidronate disodium (HEBP) and calcium plus alphacalcidol in postmenopausal osteoporosis","volume":"6","author":"Shiota","year":"2001","journal-title":"J. Orthop. Sci."},{"key":"B58","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1186\/s12891-018-2309-y","article-title":"Open-label study of treatment with alendronate sodium plus vitamin D in men and women with osteoporosis in Thailand","volume":"19","author":"Songpatanasilp","year":"2018","journal-title":"BMC Musculoskelet. Disord."},{"key":"B59","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2165\/00044011-200727060-00005","article-title":"Clodronic acid in the treatment of postmenopausal osteoporosis","volume":"27","author":"Tanakol","year":"2007","journal-title":"Clin. Drug Investig."},{"key":"B60","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/jcpt.12429","article-title":"Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis","volume":"41","author":"Tan","year":"2016","journal-title":"J. Clin. Pharm. Ther."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1096\/fj.06-6374fje","article-title":"Evidence for auto\/paracrine actions of vitamin D in bone: 1alpha-hydroxylase expression and activity in human bone cells","volume":"20","author":"VAN Driel","year":"2006","journal-title":"Faseb J."},{"key":"B62","doi-asserted-by":"publisher","first-page":"166","DOI":"10.4103\/ijpvm.IJPVM_33_19","article-title":"Therapeutic dimensions of bisphosphonates: a clinical update","volume":"11","author":"Vannala","year":"2020","journal-title":"Int. J. Prev. Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S2213-8587(22)00012-2","article-title":"Osteoporosis in men","volume":"10","author":"Vilaca","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"102234","DOI":"10.1016\/j.arr.2024.102234","article-title":"The role and mechanism of RNA-binding proteins in bone metabolism and osteoporosis","volume":"96","author":"Wu","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"B65","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00774-009-0057-7","article-title":"The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis","volume":"27","author":"Yan","year":"2009","journal-title":"J. Bone Min. Metab."},{"key":"B66","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1177\/147323001103900133","article-title":"The safety and efficacy of early-stage bi-weekly alendronate to improve bone mineral density and bone turnover in Chinese post-menopausal women at risk of osteoporosis","volume":"39","author":"You","year":"2011","journal-title":"J. Int. Med. Res."},{"key":"B67","doi-asserted-by":"publisher","first-page":"115654","DOI":"10.1016\/j.ejmech.2023.115654","article-title":"Recent advance of small-molecule drugs for clinical treatment of osteoporosis: a review","volume":"259","author":"Zhang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"B68","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1007\/s00198-015-3141-y","article-title":"Alendronate sodium\/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension","volume":"26","author":"Zhang","year":"2015","journal-title":"Osteoporos. Int."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1422062\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T04:43:27Z","timestamp":1732164207000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1422062\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":68,"alternative-id":["10.3389\/fphar.2024.1422062"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1422062","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,21]]},"article-number":"1422062"}}